WO2026119257 - DRUG FOR TREATING TRANSFORMED DIFFUSE LARGE B-CELL LYMPHOMA AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/119257
Publication Date
11.06.2026
International Application No.
PCT/CN2025/140194
International Filing Date
05.12.2025
Title **
[English]
DRUG FOR TREATING TRANSFORMED DIFFUSE LARGE B-CELL LYMPHOMA AND USE THEREOF
[French]
MÉDICAMENT POUR TRAITER LE LYMPHOME DIFFUS À GRANDES CELLULES B TRANSFORMÉ ET SON UTILISATION
[Chinese]
治疗转化型弥漫大B细胞淋巴瘤的药物及其用途
Applicants **
ZHEJIANG TERUISI PHARMACEUTICAL INC.
Inventors
HUANG, Kai
WANG, Chen
Priority Data
202411783638.7
06.12.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1749 | |
| EPO | Filing, Examination, Granting | 12088 | |
| Japan | Filing, Examination, Granting | 2186 | |
| South Korea | Filing, Examination, Granting | 2204 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,967
Contact Us
Abstract[English]
Disclosed in the present invention is the use of an anti-CD20 antibody-drug conjugate in the preparation of a drug for treating diffuse large B-cell lymphoma transformed from indolent B-cell lymphoma. The drug exhibits a good clinical efficacy in the treatment of diffuse large B-cell lymphoma transformed from indolent B-cell lymphoma, is safe and controllable, and can meet currently unmet clinical requirements.[French]
La présente invention concerne l'utilisation d'un conjugué anticorps anti-CD20-médicament dans la préparation d'un médicament pour le traitement du lymphome diffus à grandes cellules B transformé à partir d'un lymphome B indolent. Le médicament présente une bonne efficacité clinique dans le traitement du lymphome diffus à grandes cellules B transformé à partir d'un lymphome B indolent, est sûr et contrôlable, et peut répondre aux besoins cliniques actuellement non satisfaits.[Chinese]
本发明公开了一种抗CD20抗体药物偶联物在制备治疗惰性B细胞淋巴瘤转化的弥漫大B细胞淋巴瘤的药物中的用途，所述药物在治疗惰性B细胞淋巴瘤转化的弥漫大B细胞淋巴瘤上具有良好的临床疗效，安全可控，可满足目前未被满足的临床需求。